These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 29038282

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL.
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [Abstract] [Full Text] [Related]

  • 4. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence.
    Tsuchiya K, Hayashi Y, Ryu S, Tran HT, Takano M, Tanaka K, Mizushima D, Oka S, Gatanaga H, Hamada A.
    J Infect Chemother; 2024 Sep; 30(9):876-880. PubMed ID: 38431219
    [Abstract] [Full Text] [Related]

  • 5. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
    Spinelli MA, Glidden DV, Anderson PL, Gandhi M, Cohen S, Vittinghoff E, Coleman ME, Scott H, Bacon O, Elion R, Kolber MA, Buchbinder SP, Liu AY.
    J Acquir Immune Defic Syndr; 2019 Jun 01; 81(2):158-162. PubMed ID: 31095005
    [Abstract] [Full Text] [Related]

  • 6. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L, Niu X, Brunelli MK, Mugwanya KK.
    Curr HIV/AIDS Rep; 2024 Oct 01; 21(5):264-281. PubMed ID: 39120667
    [Abstract] [Full Text] [Related]

  • 7. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
    Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB.
    AIDS Res Hum Retroviruses; 2016 Jan 01; 32(1):32-43. PubMed ID: 26414912
    [Abstract] [Full Text] [Related]

  • 8. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
    Dickinson L, Yapa HM, Jackson A, Moyle G, Else L, Amara A, Khoo S, Back D, Karolia Z, Higgs C, Boffito M.
    Antimicrob Agents Chemother; 2015 Oct 01; 59(10):6080-6. PubMed ID: 26195515
    [Abstract] [Full Text] [Related]

  • 9. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
    Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR.
    Clin Infect Dis; 2018 May 02; 66(10):1566-1572. PubMed ID: 29228144
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
    Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL.
    AIDS Res Hum Retroviruses; 2013 Feb 02; 29(2):384-90. PubMed ID: 22935078
    [Abstract] [Full Text] [Related]

  • 12. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, Pathak S, Mgodi N, Bekker LG, Donnell DJ, Wilson E, Yuha K, Anderson PL, Agyei Y, Noble H, Rose SM, Baeten JM, Fogel JM, Adeyeye A, Wiesner L, Rooney J, Delany-Moretlwe S.
    PLoS Med; 2021 Jun 02; 18(6):e1003670. PubMed ID: 34143779
    [Abstract] [Full Text] [Related]

  • 13. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
    Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM, Partners Demonstration Study Team.
    AIDS; 2018 Aug 24; 32(13):1891-1898. PubMed ID: 29894385
    [Abstract] [Full Text] [Related]

  • 14. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
    van den Elshout MA, Hoornenborg E, Coyer L, Anderson PL, Davidovich U, de Vries HJ, Prins M, Schim van der Loeff MF, of the Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative (H-TEAM).
    Sex Transm Infect; 2023 Aug 24; 99(5):303-310. PubMed ID: 37258273
    [Abstract] [Full Text] [Related]

  • 15. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
    Stranix-Chibanda L, Anderson PL, Kacanek D, Hosek S, Huang S, Nematadzira TG, Taulo F, Korutaro V, Nakabiito C, Masenya M, Lypen K, Brown E, Ibrahim ME, Yager J, Wiesner L, Johnston B, Amico KR, Rooney JF, Chakhtoura N, Spiegel HML, Chi BH, IMPAACT 2009 Team.
    Clin Infect Dis; 2021 Oct 05; 73(7):e1893-e1900. PubMed ID: 33341883
    [Abstract] [Full Text] [Related]

  • 16. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
    Aizire J, Brooks KM, Mirochnick M, Flynn PM, Butler K, Kiser JJ, Siberry GK, Fenton T, Cababasay M, Fowler MG, PROMISE Study Team.
    J Acquir Immune Defic Syndr; 2020 Feb 01; 83(2):173-180. PubMed ID: 31929405
    [Abstract] [Full Text] [Related]

  • 17. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
    Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL.
    PLoS One; 2016 Feb 01; 11(11):e0165505. PubMed ID: 27832147
    [Abstract] [Full Text] [Related]

  • 18. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
    Phillips TK, Sinxadi P, Abrams EJ, Zerbe A, Orrell C, Hu NC, Brittain K, Gomba Y, Norman J, Wiesner L, Myer L, Maartens G.
    J Acquir Immune Defic Syndr; 2019 Jul 01; 81(3):311-318. PubMed ID: 30893125
    [Abstract] [Full Text] [Related]

  • 19. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
    Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL.
    Clin Infect Dis; 2019 Apr 08; 68(8):1335-1342. PubMed ID: 30137238
    [Abstract] [Full Text] [Related]

  • 20. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
    Yager JL, Coyle RP, Coleman SS, Ellison L, Zheng JH, Bushman L, Gardner EM, Morrow M, MaWhinney S, Anderson PL, Justice Kiser J, Castillo-Mancilla JR.
    J Int Assoc Provid AIDS Care; 2019 Apr 08; 18():2325958219888457. PubMed ID: 31750768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.